Cargando…
Clinical profile and management of rivaroxaban in patients with atrial fibrillation in routine practice in Spain: data from six nationwide studies
AIMS: To analyze the clinical profile and management of patients with nonvalvular atrial fibrillation taking rivaroxaban in routine practice in Spain. METHODS: Clinical data from the observational studies HEROIC (cardiology and hematology; n=1,727), EMIR (cardiology; n=1,493), BRONCE-AP (primary car...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioExcel Publishing Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822684/ https://www.ncbi.nlm.nih.gov/pubmed/31692949 http://dx.doi.org/10.7573/dic.212606 |
_version_ | 1783464383295258624 |
---|---|
author | Anguita, Manuel de la Figuera, Mariano Cabeza, Alejandro I Pérez Fernández, Carmen Suarez |
author_facet | Anguita, Manuel de la Figuera, Mariano Cabeza, Alejandro I Pérez Fernández, Carmen Suarez |
author_sort | Anguita, Manuel |
collection | PubMed |
description | AIMS: To analyze the clinical profile and management of patients with nonvalvular atrial fibrillation taking rivaroxaban in routine practice in Spain. METHODS: Clinical data from the observational studies HEROIC (cardiology and hematology; n=1,727), EMIR (cardiology; n=1,493), BRONCE-AP (primary care; n=133), SILVER-AP (primary care; n=457), ALADIN (internal medicine and neurology; n=249), and ESPARTA (internal medicine; n=110) of patients taking rivaroxaban were analyzed. The clinical profile was compared with those of the XANTUS and ROCKET-AF studies. RESULTS: Overall, mean age was 74.9±9.4 years, CHA(2)DS(2)-VASc score was 3.7±1.5, and 43.2% had a HAS-BLED score ≥3. Patients included in the HEROIC and EMIR studies were older and more frequently had a creatinine clearance <50 mL/min and a higher thromboembolic risk than those in the XANTUS study, and patients included in the ALADIN study were older and had more prior cerebrovascular disease, but a lower thromboembolic risk than those in the ROCKET-AF trial. In those studies with available data, medication adherence and satisfaction with rivaroxaban were high. CONCLUSION: Bearing in mind differences according to the clinical setting of each study, atrial fibrillation patients taking rivaroxaban in Spain were elderly and had a high thromboembolic risk. Medication adherence and satisfaction with rivaroxaban were high. |
format | Online Article Text |
id | pubmed-6822684 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioExcel Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-68226842019-11-05 Clinical profile and management of rivaroxaban in patients with atrial fibrillation in routine practice in Spain: data from six nationwide studies Anguita, Manuel de la Figuera, Mariano Cabeza, Alejandro I Pérez Fernández, Carmen Suarez Drugs Context Original Research AIMS: To analyze the clinical profile and management of patients with nonvalvular atrial fibrillation taking rivaroxaban in routine practice in Spain. METHODS: Clinical data from the observational studies HEROIC (cardiology and hematology; n=1,727), EMIR (cardiology; n=1,493), BRONCE-AP (primary care; n=133), SILVER-AP (primary care; n=457), ALADIN (internal medicine and neurology; n=249), and ESPARTA (internal medicine; n=110) of patients taking rivaroxaban were analyzed. The clinical profile was compared with those of the XANTUS and ROCKET-AF studies. RESULTS: Overall, mean age was 74.9±9.4 years, CHA(2)DS(2)-VASc score was 3.7±1.5, and 43.2% had a HAS-BLED score ≥3. Patients included in the HEROIC and EMIR studies were older and more frequently had a creatinine clearance <50 mL/min and a higher thromboembolic risk than those in the XANTUS study, and patients included in the ALADIN study were older and had more prior cerebrovascular disease, but a lower thromboembolic risk than those in the ROCKET-AF trial. In those studies with available data, medication adherence and satisfaction with rivaroxaban were high. CONCLUSION: Bearing in mind differences according to the clinical setting of each study, atrial fibrillation patients taking rivaroxaban in Spain were elderly and had a high thromboembolic risk. Medication adherence and satisfaction with rivaroxaban were high. BioExcel Publishing Ltd 2019-10-09 /pmc/articles/PMC6822684/ /pubmed/31692949 http://dx.doi.org/10.7573/dic.212606 Text en Copyright © 2019 Anguita M, de la Figuera M, Pérez Cabeza AI, Suarez Fernández C. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission. |
spellingShingle | Original Research Anguita, Manuel de la Figuera, Mariano Cabeza, Alejandro I Pérez Fernández, Carmen Suarez Clinical profile and management of rivaroxaban in patients with atrial fibrillation in routine practice in Spain: data from six nationwide studies |
title | Clinical profile and management of rivaroxaban in patients with atrial fibrillation in routine practice in Spain: data from six nationwide studies |
title_full | Clinical profile and management of rivaroxaban in patients with atrial fibrillation in routine practice in Spain: data from six nationwide studies |
title_fullStr | Clinical profile and management of rivaroxaban in patients with atrial fibrillation in routine practice in Spain: data from six nationwide studies |
title_full_unstemmed | Clinical profile and management of rivaroxaban in patients with atrial fibrillation in routine practice in Spain: data from six nationwide studies |
title_short | Clinical profile and management of rivaroxaban in patients with atrial fibrillation in routine practice in Spain: data from six nationwide studies |
title_sort | clinical profile and management of rivaroxaban in patients with atrial fibrillation in routine practice in spain: data from six nationwide studies |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822684/ https://www.ncbi.nlm.nih.gov/pubmed/31692949 http://dx.doi.org/10.7573/dic.212606 |
work_keys_str_mv | AT anguitamanuel clinicalprofileandmanagementofrivaroxabaninpatientswithatrialfibrillationinroutinepracticeinspaindatafromsixnationwidestudies AT delafigueramariano clinicalprofileandmanagementofrivaroxabaninpatientswithatrialfibrillationinroutinepracticeinspaindatafromsixnationwidestudies AT cabezaalejandroiperez clinicalprofileandmanagementofrivaroxabaninpatientswithatrialfibrillationinroutinepracticeinspaindatafromsixnationwidestudies AT fernandezcarmensuarez clinicalprofileandmanagementofrivaroxabaninpatientswithatrialfibrillationinroutinepracticeinspaindatafromsixnationwidestudies |